Silexion Therapeutics Ltd. (SLXNW)

IL — Healthcare Sector
Peers: REVB  VRPX  AKTX  CDT  DRMA  PPBT  XAGE  PBM  BDRX  MSPR 

Automate Your Wheel Strategy on SLXNW

With Tiblio's Option Bot, you can configure your own wheel strategy including SLXNW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SLXNW
  • Rev/Share 0.0
  • Book/Share 0.2071
  • PB 0.1883
  • Debt/Equity 30.8167
  • CurrentRatio 2.4358
  • ROIC -3.634

 

  • MktCap 21878.0
  • FreeCF/Share -18.2254
  • PFCF -0.0021
  • PE -0.0013
  • Debt/Assets 0.6379
  • DivYield 0
  • ROE 12.1706

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Silexion Therapeutics Ltd. (SLXNW)

  • IPO Date 2024-08-16
  • Website https://silexion.com
  • Industry Biotechnology
  • CEO Ilan Hadar
  • Employees 11
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.